Hematuria Treatment Market Scope And Analysis

Hematuria Treatment Market Report Scope

Hematuria Treatment Market News and Recent Developments

The Hematuria Treatment Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the hematuria treatment market are listed below:

• AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (CHF), and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.1 Farxiga was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF). (Source: AstraZeneca’s, Company Website, May 2023)

Hematuria Treatment Market Report Coverage and Deliverables

The “Hematuria Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Hematuria treatment market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Hematuria treatment market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Hematuria treatment market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the hematuria treatment market
• Detailed company profiles